Controlled and Targeted Drug Delivery by a UV-responsive Liposome for Overcoming Chemo-resistance in Non-Hodgkin Lymphoma.
Although chemotherapy plays a vital role in treating non-Hodgkin lymphomas, the clinical applications are limited because of intolerable side-effects and multidrug resistance at the beginning or during the course of therapy. In this study, we successfully fabricated a CD20-targeting immuno-liposome based on 1,2-bis(10,12-tricosadiynoyl)-sn-glycero-3-phosphocholine (DC-8,9PC), which can form intermolecular cross-linking through the diacetylenic group by ultraviolet irradiation. This immuno-liposome showed appropriate size distribution, well-defined regular spherical structure, favorable biocompatibility, high serum stability, and prolonged circulation time in blood vessels. The in and ex vivo experiments demonstrate enhanced tumor suppression abilities against both wild-type and resistant non-Hodgkin lymphomas for liposomal doxorubicin when compared with free drugs. The outstanding antitumor activities are attributed to the accumulation and retention of liposomal drugs in malignant tissues and cells, which are realized by the co-operation of active targeting via antibody-antigen reaction and passive targeting via enhanced permeability and retention effect.
Tumor Immunology and Gene Therapy Center, Eastern Hepatobiliary Surgery Hospital affiliated to the Second Military Medical University, 225 Changhai Road, Shanghai, 200433, China.|International Joint Cancer Institute, the Second Military Medical University, 800 Xiangyin Road, Shanghai, 200433, China.
Huafei
H
Li
Department of General Surgery/Hematology, Yancheng City No. 1 People's Hospital affiliated to Nantong Medical Collage, 16th Yuehe Road, Yancheng, Jiangsu Province, 224005, China.
Kun
K
Guo
Department of Laboratory Diagnosis, Changhai Hospital affiliated to the Second Military Medical University, 168 Changhai Road, Shanghai, 200433, China.
Cong
C
Wu
Department of General Surgery/Hematology, Yancheng City No. 1 People's Hospital affiliated to Nantong Medical Collage, 16th Yuehe Road, Yancheng, Jiangsu Province, 224005, China.
Ling
L
Shu
Tumor Immunology and Gene Therapy Center, Eastern Hepatobiliary Surgery Hospital affiliated to the Second Military Medical University, 225 Changhai Road, Shanghai, 200433, China.
Shiwei
S
Guo
Department of Pharmacy, Changhai Hospital affiliated to the Second Military Medical University, 168 Changhai Road, Shanghai, 200433, China.
Jing
J
Hou
Department of Pharmacy, Changhai Hospital affiliated to the Second Military Medical University, 168 Changhai Road, Shanghai, 200433, China.
Naping
N
Zhao
Tumor Immunology and Gene Therapy Center, Eastern Hepatobiliary Surgery Hospital affiliated to the Second Military Medical University, 225 Changhai Road, Shanghai, 200433, China.
Lixin
L
Wei
Tumor Immunology and Gene Therapy Center, Eastern Hepatobiliary Surgery Hospital affiliated to the Second Military Medical University, 225 Changhai Road, Shanghai, 200433, China.
Xiaobo
X
Man
Department of Pharmacy, Changhai Hospital affiliated to the Second Military Medical University, 168 Changhai Road, Shanghai, 200433, China.
Li
L
Zhang
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D055910:Antibodies, Immobilized / Q000737:chemistry / Q000276:immunology; D018951:Antigens, CD20 / Q000276:immunology; D045744:Cell Line, Tumor; D003692:Delayed-Action Preparations / Q000737:chemistry*; D053280:Diynes / Q000737:chemistry*; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D016503:Drug Delivery Systems; D005260:Female; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000737:chemistry / Q000276:immunology; D008081:Liposomes / Q000737:chemistry* / Q000276:immunology; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000276:immunology; D016513:Mice, SCID; D010713:Phosphatidylcholines / Q000737:chemistry*; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D000069283:Rituximab / Q000737:chemistry / Q000276:immunology; D014466:Ultraviolet Rays
D000903:Antibiotics, Antineoplastic; D055910:Antibodies, Immobilized; D018951:Antigens, CD20; D003692:Delayed-Action Preparations; D053280:Diynes; D007140:Immunoglobulin Fab Fragments; D008081:Liposomes; D010713:Phosphatidylcholines; C506643:liposomal doxorubicin; D011092:Polyethylene Glycols; D000069283:Rituximab; C053923:1,2-bis(10,12-tricosadiynoyl)phosphatidylcholine; D004317:Doxorubicin
CD20; chemotherapy; liposome; multidrug resistance; non-Hodgkin lymphoma; serum stability